Total Payments
$1.4M
2024 Payments
$98,359
Companies
28
Transactions
1,272
Payment Breakdown by Category
Consulting$639,484 (44.8%)
Other$436,218 (30.5%)
Travel$241,351 (16.9%)
Research$89,464 (6.3%)
Food & Beverage$21,594 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $639,484 | 168 | 44.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $409,143 | 96 | 28.6% |
| Travel and Lodging | $241,351 | 465 | 16.9% |
| Unspecified | $89,464 | 132 | 6.3% |
| Honoraria | $26,075 | 11 | 1.8% |
| Food and Beverage | $21,594 | 399 | 1.5% |
| Grant | $1,000 | 1 | 0.1% |
Payments by Type
General
$1.3M
1,140 transactions
Research
$89,464
132 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $449,419 | 458 | $0 (2024) |
| GENZYME CORPORATION | $398,925 | 249 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $145,112 | 176 | $0 (2024) |
| PFIZER INC. | $94,167 | 61 | $0 (2024) |
| Eli Lilly and Company | $74,408 | 98 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $61,510 | 31 | $0 (2023) |
| ABBVIE INC. | $45,026 | 52 | $0 (2024) |
| LEO Pharma Inc. | $43,063 | 19 | $0 (2024) |
| Dermavant Sciences, Inc. | $38,719 | 50 | $0 (2024) |
| UCB SA | $18,172 | 11 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98,359 | 90 | GENZYME CORPORATION ($31,270) |
| 2023 | $120,539 | 103 | SANOFI-AVENTIS U.S. LLC ($35,717) |
| 2022 | $103,225 | 81 | GENZYME CORPORATION ($45,140) |
| 2021 | $122,743 | 64 | Regeneron Healthcare Solutions, Inc. ($32,398) |
| 2020 | $116,262 | 75 | PFIZER INC. ($28,709) |
| 2019 | $296,000 | 319 | Regeneron Healthcare Solutions, Inc. ($113,121) |
| 2018 | $323,223 | 315 | Regeneron Healthcare Solutions, Inc. ($157,878) |
| 2017 | $247,760 | 225 | Regeneron Healthcare Solutions, Inc. ($120,768) |
All Payment Transactions
1,272 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,584.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,796.00 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $90.63 | General |
| Category: Dermatology | ||||||
| 12/03/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: DERMATOLOGY | ||||||
| 11/19/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis • Category: Immunology | ||||||
| 11/19/2024 | Amgen Inc. | — | Travel and Lodging | Cash or cash equivalent | $164.20 | General |
| 11/19/2024 | Amgen Inc. | — | Food and Beverage | Cash or cash equivalent | $32.53 | General |
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Consulting Fee | Cash or cash equivalent | $7,670.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $566.95 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $282.56 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $220.54 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | Cash or cash equivalent | $153.10 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $134.71 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $73.62 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $46.86 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | Cash or cash equivalent | $45.12 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $41.76 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $34.56 | General |
| Category: DERMATOLOGY | ||||||
| 11/08/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $682.33 | General |
| 11/08/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $300.00 | General |
| 11/08/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $223.44 | General |
| 11/02/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Consulting Fee | Cash or cash equivalent | $7,670.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/02/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $362.95 | General |
| Category: DERMATOLOGY | ||||||
| 11/02/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $241.25 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $23,271 | 29 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $23,010 | 21 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $8,416 | 20 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $8,377 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $6,978 | 15 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $6,695 | 10 |
| AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $4,920 | 15 |
| A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months to < 6 Years With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $1,750 | 5 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients greater than or equal to 12 to less than 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | GENZYME CORPORATION | $1,250 | 1 |
| An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | GENZYME CORPORATION | $1,250 | 3 |
| Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to Severe Atopic Dermatitis | GENZYME CORPORATION | $1,250 | 3 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | Regeneron Pharmaceuticals, Inc. | $847.75 | 2 |
| A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $750.00 | 2 |
| Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Pediatric Patients With Moderate to Severe Atopic Dermatitis | GENZYME CORPORATION | $500.00 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, 6 Years to 12 Years of Age, With Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $199.38 | 1 |
About Dr. Mark Boguniewicz, MD
Dr. Mark Boguniewicz, MD is a Allergy healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790796555.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Boguniewicz, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $98,359 received in 2024. These payments were reported across 1,272 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($639,484).
Ad
Practice Information
- Specialty Allergy
- Location Denver, CO
- Active Since 08/10/2006
- Last Updated 11/12/2020
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1790796555
Products in Payments
- DUPIXENT (Biological) $408,694
- DUPIXENT DUPILUMAB INJECTION (Biological) $313,199
- DUPIXENT (Drug) $207,030
- ATOPIC DERMATITIS - DISEASE (Drug) $48,784
- EUCRISA (Drug) $37,016
- NO PRODUCT DISCUSSED (Drug) $36,799
- TAPINAROF (Drug) $28,985
- CIBINQO (Drug) $20,513
- VTAMA (Drug) $9,734
- RINVOQ (Biological) $9,310
- Zoryve (Drug) $3,629
- Humira (Biological) $924.43
- SKYRIZI (Drug) $624.28
- ADBRY (Biological) $152.36
- ACTIMMUNE (Drug) $135.53
- Grastek (Drug) $109.97
- NUCALA (Biological) $95.65
- ORALAIR (Biological) $93.21
- DISEASE STATE (Drug) $87.77
- TEZSPIRE (Biological) $67.86
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.